Long-term safety study of buntanetap for people with Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study follows people who have already taken buntanetap in an earlier Alzheimer's trial. It checks the medicine's long-term safety and how well people tolerate it over more time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken buntanetap in a previous Alzheimer's clinical trial.
- You need a study partner who can spend at least 10 hours a week with you and go with you to study visits.
- Women who could become pregnant must use highly effective birth control and have a negative pregnancy test. Men must agree not to father a child and use a barrier method.
- Your overall health and memory should be good enough for you to give consent, though a legal representative can help if your memory score is low.
- You need to be free of serious suicidal thoughts or attempts in the past month.
- You must be able to see, hear, and move well enough to complete the study tests and be in good general health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This study tests whether a water pill called bumetanide can help people with early Alzheimer's disease. It involves taking the study drug, having MRI scans, and doing memory tests to see if it slows down symptoms.
This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.
This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Hear when a new Alzheimer's Dementia (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.